學門類別
哈佛
- General Management
- Marketing
- Entrepreneurship
- International Business
- Accounting
- Finance
- Operations Management
- Strategy
- Human Resource Management
- Social Enterprise
- Business Ethics
- Organizational Behavior
- Information Technology
- Negotiation
- Business & Government Relations
- Service Management
- Sales
- Economics
- Teaching & the Case Method
最新個案
- A practical guide to SEC ï¬nancial reporting and disclosures for successful regulatory crowdfunding
- Quality shareholders versus transient investors: The alarming case of product recalls
- The Health Equity Accelerator at Boston Medical Center
- Monosha Biotech: Growth Challenges of a Social Enterprise Brand
- Assessing the Value of Unifying and De-duplicating Customer Data, Spreadsheet Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise, Data Supplement
- Building an AI First Snack Company: A Hands-on Generative AI Exercise
- Board Director Dilemmas: The Tradeoffs of Board Selection
- Barbie: Reviving a Cultural Icon at Mattel (Abridged)
- Happiness Capital: A Hundred-Year-Old Family Business's Quest to Create Happiness
Takeda Pharmaceutical Company: Becoming a Global Company A
內容大綱
In 2007, Takeda was a leading Japanese pharmaceutical company with sales primarily in Japan and the U.S. Although Takeda ranked around 15th in global sales, the pharmaceutical market had been shifting due to major industry consolidation. Yasuchika Hasegawa, the president of Takeda, was concerned about the future of the company. To counter the shrinking Japanese pharmaceutical market, Takeda had expanded its business to overseas markets. But Takeda's attempts to become a global company had been criticized as slow and not sufficiently aggressive. One reason for this was Takeda's risk-averse corporate culture. Worse, Takeda's R&D pipeline was shrinking, and patents on several of its major products were about to expire-which would inevitably lead to a decline in profits as generics entered the market. This case explores Hasegawa's plan to transform Takeda into a global pharmaceutical company in a rapidly changing market. It covers Takeda's history, industry trends, and Hasegawa's acquisition strategies.